116 related articles for article (PubMed ID: 26665182)
41. Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors.
Agrawal S; Kandimalla ER
Immunooncol Technol; 2019 Oct; 3():15-23. PubMed ID: 35757301
[TBL] [Abstract][Full Text] [Related]
42. Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis.
Rafael TS; Rotman J; Brouwer OR; van der Poel HG; Mom CH; Kenter GG; de Gruijl TD; Jordanova ES
J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207374
[TBL] [Abstract][Full Text] [Related]
43. A model of impaired Langerhans cell maturation associated with HPV induced epithelial hyperplasia.
Tuong ZK; Lukowski SW; Nguyen QH; Chandra J; Zhou C; Gillinder K; Bashaw AA; Ferdinand JR; Stewart BJ; Teoh SM; Hanson SJ; Devitt K; Clatworthy MR; Powell JE; Frazer IH
iScience; 2021 Nov; 24(11):103326. PubMed ID: 34805788
[TBL] [Abstract][Full Text] [Related]
44. The Immune Microenvironment in Human Papilloma Virus-Induced Cervical Lesions-Evidence for Estrogen as an Immunomodulator.
R S J
Front Cell Infect Microbiol; 2021; 11():649815. PubMed ID: 33996630
[TBL] [Abstract][Full Text] [Related]
45. Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System.
Zhou C; Tuong ZK; Frazer IH
Front Oncol; 2019; 9():682. PubMed ID: 31428574
[TBL] [Abstract][Full Text] [Related]
46. CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8
Westrich JA; Vermeer DW; Silva A; Bonney S; Berger JN; Cicchini L; Greer RO; Song JI; Raben D; Slansky JE; Lee JH; Spanos WC; Pyeon D
Oncogene; 2019 Nov; 38(46):7166-7180. PubMed ID: 31417179
[TBL] [Abstract][Full Text] [Related]
47. The Interaction Between Human Papillomaviruses and the Stromal Microenvironment.
Woodby B; Scott M; Bodily J
Prog Mol Biol Transl Sci; 2016; 144():169-238. PubMed ID: 27865458
[TBL] [Abstract][Full Text] [Related]
48. T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation.
Woodham AW; Yan L; Skeate JG; van der Veen D; Brand HH; Wong MK; Da Silva DM; Kast WM
Papillomavirus Res; 2016 Dec; 2():21-30. PubMed ID: 27182559
[TBL] [Abstract][Full Text] [Related]
49. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.
Skeate JG; Woodham AW; Einstein MH; Da Silva DM; Kast WM
Hum Vaccin Immunother; 2016 Jun; 12(6):1418-29. PubMed ID: 26835746
[TBL] [Abstract][Full Text] [Related]
50. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.
Da Silva DM; Woodham AW; Naylor PH; Egan JE; Berinstein NL; Kast WM
J Interferon Cytokine Res; 2016 May; 36(5):291-301. PubMed ID: 26653678
[TBL] [Abstract][Full Text] [Related]
51. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.
Fahey LM; Raff AB; Da Silva DM; Kast WM
J Immunol; 2009 Mar; 182(5):2919-28. PubMed ID: 19234187
[TBL] [Abstract][Full Text] [Related]
52. Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.
Da Silva DM; Movius CA; Raff AB; Brand HE; Skeate JG; Wong MK; Kast WM
Virology; 2014 Mar; 452-453():279-86. PubMed ID: 24606705
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.
Woodham AW; Raff AB; Raff LM; Da Silva DM; Yan L; Skeate JG; Wong MK; Lin YG; Kast WM
J Immunol; 2014 May; 192(10):4748-57. PubMed ID: 24719459
[TBL] [Abstract][Full Text] [Related]
54. Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C.
Da Silva DM; Woodham AW; Rijkee LK; Skeate JG; Taylor JR; Koopman ME; Brand HE; Wong MK; McKee GM; Salazar AM; Kast WM
Papillomavirus Res; 2015 Dec; 1():12-21. PubMed ID: 26665182
[TBL] [Abstract][Full Text] [Related]
55. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.
Da Silva DM; Woodham AW; Skeate JG; Rijkee LK; Taylor JR; Brand HE; Muderspach LI; Roman LD; Yessaian AA; Pham HQ; Matsuo K; Lin YG; McKee GM; Salazar AM; Kast WM
Clin Immunol; 2015 Dec; 161(2):197-208. PubMed ID: 26360252
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
